Bristol-Myers Squibb Co. (BMY)

47.63
NYSE : Health Technology
Prev Close 47.46
Day Low/High 47.24 / 47.80
52 Wk Low/High 42.48 / 63.69
Avg Volume 12.79M
Exchange NYSE
Shares Outstanding 1.64B
Market Cap 76.85B
EPS 3.00
Div & Yield 1.64 (3.47%)

Latest News

Big Pharma Sees Pockets of Recent Insider Buying

Big Pharma Sees Pockets of Recent Insider Buying

AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.

Jim Cramer: 7 Sectors You Can Buy as the Trade War Continues

Jim Cramer: 7 Sectors You Can Buy as the Trade War Continues

These stocks and sectors are safe havens, and may even be opportunities.

3 Trends Driving This Earnings Season

3 Trends Driving This Earnings Season

With a third of S&P 500 stocks having reported, these 3 trends are coming to the fore.

Jim Cramer: Add 'Better Than Feared' to Your Investing Lexicon

Jim Cramer: Add 'Better Than Feared' to Your Investing Lexicon

Here's the only way to explain why stocks jump like mad if the companies underneath them only perform slightly better than the analysts worried they would.

High Flyers and Low Flyers

Equities are a bit higher across the board since our last update. Homebuilders continue to be in the green as 30-year mortgage rates hover near three-year lows. This is starting to have an effect as purchase application demand has posted its biggest...

SOX It to Me, Military Mischief in Asia, and Awaiting Amazon: Market Recon

SOX It to Me, Military Mischief in Asia, and Awaiting Amazon: Market Recon

And as the semiconductor sector continues to shine, Brooks Automation is a name to keep in mind.

Jim Cramer: Big Tech in Washington Will Mean an EPS Hit

Jim Cramer: Big Tech in Washington Will Mean an EPS Hit

Breaking down the impact on Facebook, Alphabet and Amazon of congressional hearings.

Watch These 4 Japanese Drugmakers With Big Coming Events

Watch These 4 Japanese Drugmakers With Big Coming Events

Investors should keep tabs on these "focus events" from this quartet of U.S.-listed Japanese drugmakers that can make or break their treatments.

My 3 Predictions for the Second Half of 2019

My 3 Predictions for the Second Half of 2019

Watch the Russell 2000, housing activity, and mergers and acquisitions.

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.

Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition

Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition

Despite the financial positivity, many analysts warn the deal could have hiccups ahead.

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.

Bristol-Myers Continues to Show Bottoming Price Action on the Charts

Bristol-Myers Continues to Show Bottoming Price Action on the Charts

Let's check out the charts of BMY.

IPO Gives Chinese Couple a 'Hansoh' Sum

IPO Gives Chinese Couple a 'Hansoh' Sum

The initial public offering of Hansoh Pharmaceutical Group made the Chinese couple Zhong Huijuan and Sun Piaoyang the richest in the nation.

China's Drugmakers Under Scrutiny After Stanford Admissions Scandal

China's Drugmakers Under Scrutiny After Stanford Admissions Scandal

Chinese authorities are auditing the books of 77 drugmakers, including three multinationals, they say were selected at random. Were they motivated by embarrassment over a college-admissions payment made by a Chinese pharmaceuticals' tycoon?

A Six-Pack of Biotech Best Bets

A Six-Pack of Biotech Best Bets

Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.

Jim Cramer: What Do Trump's Whims Per Share Look Like?

Jim Cramer: What Do Trump's Whims Per Share Look Like?

What happened to the business president? I think what happened is that the polls are showing that whatever the president is doing is working.

Bristol-Myers Squibb: A Long Idea for Aggressive Traders Only

Bristol-Myers Squibb: A Long Idea for Aggressive Traders Only

BMY is not 'out of the woods' yet, but aggressive traders could probe the long side here.

Jim Cramer: It Isn't a Slowdown That I Fear, It's a Tweet

Jim Cramer: It Isn't a Slowdown That I Fear, It's a Tweet

This is the first time I can ever recall when a president is so attuned to the market that he will bend to its wishes.

Jim Cramer: What to Buy and What to Avoid on Trump's Latest China Tweet

Jim Cramer: What to Buy and What to Avoid on Trump's Latest China Tweet

As usual, the stocks that bounce back first are the tech stocks with little Chinese exposure and the consumer packaged goods that just demonstrated good numbers.

Jim Cramer: My Bet's on the 'Ladies' in This Year's Draft

Jim Cramer: My Bet's on the 'Ladies' in This Year's Draft

Analyzing this year's stock draft contest and individual stock-picking vs. indexing.

Keep Your Eye on the Oncology Sector Among Biotech Stocks

Keep Your Eye on the Oncology Sector Among Biotech Stocks

The myriad names in oncology have been the hottest area for acquisitions along with gene therapy.

Seattle Genetics Struggles as Other Biotech Stocks Rise

Market is pretty much where it has been all day, nicely positive across the board. Biotech up nearly 2% on the day. Gilead Sciences, Inc. , and Celgene Corp. , are two large caps on the move for reasons we covered in previous posts. The Bristol-Myer...

A Solid Start for the Market

We are currently in process of restoring my access that is blocking me from seeing or commenting on the Daily Diary. We hope to have the problem resolved soon. Our apologies while getting the issue resolved. The market is off to a solid start this F...

Future Brightens for 2 Small Biotech Stocks

Future Brightens for 2 Small Biotech Stocks

The biotech sector isn't for the faint of heart, but these two companies issued promising news this week.

Activists Aim to Eliminate Dual Role for Allergan CEO Saunders

Activists Aim to Eliminate Dual Role for Allergan CEO Saunders

David Tepper's Appaloosa LP renews calls for changes at the top.

I Like the Long Side of Bristol-Myers Squibb

I Like the Long Side of Bristol-Myers Squibb

Let's see what the charts and indicators look like.